CoChat

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression

Open access
Rusan, Maria, Li, Kapsok, Li, Yvonne, Christensen, Camilla L., Abraham, Brian J., Kwiatkowski, Nicholas, Buczkowski, Kevin A., Bockorny, Bruno, Chen, Ting, Li, Shuai, Rhee, Kevin, Zhang, Haikuo, Chen, Wankun, Terai, Hideki, Tavares, Tiffany, Leggett, Alan L., Li, Tianxia, Wang, Yichen, Zhang, Tinghu, Kim, Tae-Jung, Hong, Sook-Hee, Poudel-Neupane, Neermala, Silkes, Michael, Mudianto, Tenny, Tan, Li, Shimamura, Takeshi, Meyerson, Matthew, Bass, Adam J., Watanabe, Hideo, Gray, Nathanael S., Young, Richard A., Wong, Kwok-Kin, Hammerman, Peter S. · 2018 · Cancer Discovery
Cited by 131

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Acquired drug resistance is a major factor limiting the effectiveness of targeted cancer therapies. Targeting tumors with kinase inhibitors induces complex adaptive programs that promote the persistence of a fraction of the original cell population, facilitating the eventual outgrowth of inhibitor-resistant tumor clones. We show that the addition of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and in vivo cancer models. We propose that targeted therapy induces a state of transcriptional dependency in a subpopulation of cells poised to become drug tolerant, which THZ1 can exploit by blocking dynamic transcriptional responses, promoting remodeling of enhancers and key signaling outputs required for tumor cell survival in the setting of targeted therapy. These findings suggest that the addition of THZ1 to targeted therapies is a promising broad-based strategy to hinder the emergence of drug-resistant cancer cell populations. Significance: CDK7/12 inhibition prevents active enhancer formation at genes, promoting resistance emergence in response to targeted therapy, and impedes the engagement of transcriptional programs required for tumor cell survival. CDK7/12 inhibition in combination with targeted cancer therapies may serve as a therapeutic paradigm for enhancing the effectiveness of targeted therapies. Cancer Discov; 8(1); 59–73. ©2017 AACR. See related commentary by Carugo and Draetta, p. 17. This article is highlighted in the In This Issue feature, p. 1

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-0461

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 131

Metadata

Authors
Rusan, M., Li, K., Li, Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., Rhee, K., Zhang, H., Chen, W., Terai, H., Tavares, T., Leggett, A. L., Li, T., Wang, Y., Zhang, T., Kim, T.-J., Hong, S.-H., Poudel-Neupane, N., Silkes, M., Mudianto, T., Tan, L., Shimamura, T., Meyerson, M., Bass, A. J., Watanabe, H., Gray, N. S., Young, R. A., Wong, K.-K., & Hammerman, P. S.
Venue
Cancer Discovery
Published
2018-01-01
Volume
8
Issue
1
Pages
59-73
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2765438409
Cited by
131
References
23
FWCI
4.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-0461
The paper
Rusan, M., Li, K., Li, Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., Rhee, K., Zhang, H., Chen, W., Terai, H., Tavares, T., Leggett, A. L., Li, T., Wang, Y., Zhang, T., . . . Hammerman, P. S. (2018). Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-0461

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.